Table 4.
Correlations between the protein/mRNA expressions of MMP11 and P14ARF with clinical pathological characteristics in 75 LSCC cases
| Factors | Cases (%) | TBX2 | P21 | ||
|---|---|---|---|---|---|
|
| |||||
| Protein-positive N (%) | mRNA-upregulated N (%) | Protein-positive N (%) | mRNA-upregulated N (%) | ||
| Age (years) | |||||
| ≥ 60 | 32 (42.7%) | 24 (75.0%) | 27 (84.4%) | 11 (34.4%) | 9 (28.1%) |
| < 60 | 43 (57.3%) | 31 (72.1%) | 31 (72.1%) | 20 (46.5%) | 14 (32.6%) |
| Gender | |||||
| Male | 67 (89.2%) | 49 (73.1%) | 52 (77.6%) | 27 (40.3%) | 20 (29.9%) |
| Female | 8 (10.8%) | 6 (75.0%) | 6 (75.0%) | 4 (50.0%) | 3 (37.5%) |
| Tumor stage | |||||
| I-II | 24 (32.0%) | 17 (70.8%) | 19 (79.2%) | 16 (66.7%) | 17 (70.8 %) |
| III-IV | 51 (68.0%) | 38 (74.5%) | 39 (76.5%) | 15 (29.4%)a | 6 (11.8%)a |
| Lymph node metastasis | |||||
| Absent | 30 (40.0%) | 15 (50.0%) | 17 (56.7%) | 7 (23.3%) | 5 (16.7%) |
| Present | 45 (60.0%) | 40 (88.9%)a | 41 (91.1%)a | 24 (53.3%)a | 18 (40.0%a |
| Differentiation degree | |||||
| High | 27 (36.0%) | 15 (55.6%) | 16 (59.3%) | 10 (37.0%) | 7 (25.9%) |
| M.-low | 48 (64.0%) | 40 (83.3%)a | 42 (87.5%)a | 21 (43.8%) | 16 (33.3%) |
| Smoking | |||||
| Ever | 57 (76.0%) | 46 (80.7%) | 48 (84.2%) | 17 (29.8%) | 11 (19.3%) |
| Never | 18 (24.0%) | 9 (50.0%)a | 10 (55.6%)a | 14 (77.8%)a | 12 (70.6%)a |
| Alcohol | |||||
| Ever | 58 (77.3%) | 42 (72.4%) | 46 (79.3%) | 25 (43.1%) | 16 (27.6%) |
| Never | 17 (22.7%) | 13 (76.5%) | 12 (70.6%) | 6 (35.3%) | 7 (41.2%) |
| Treatment | |||||
| Surgery only | 34 (45.7) | 25 (73.5) | 24 (70.6) | 23 (67.6) | 26 (76.5) |
| Combined | 41 (54.3) | 30 (73.2) | 31 (75.6) | 32 (78.0) | 29 (70.7) |
a
P < 0.05;
M., moderate.